AstraZeneca’s rare-disease partners (Alexion) welcome investigator-initiated proposals on haematologic, metabolic, and immunologic orphan conditions. Research areas range from complement-mediated disorders to ultra-rare enzymopathies, with emphasis on translational models and natural-history studies.
Eligibility Criteria:
-
External investigators at specialised rare-disease centres.
-
Protocols must involve Alexion-licensed assets or unbranded exploratory work.
-
Ethical and regulatory approvals required before submission.
Funding Details:
-
Support Type: Drug-only supply, assay development, registry access, and translational-lab collaborations.
-
Submission Process: Proposals submitted via the Alexion iEnvision portal.
Deadline:
Ongoing intake; portal registration required.
Where to Go for Further Information:
Register in iEnvision.